In Brief The bridge formed by the Fc domain between the HSV1-infected cell and the NK cell results in NK cell activation and lysis of the HSV1-infected cell in the absence of HSV1-specific antibody in vitro and prevents fatal HSV1 infection in vivo. This mechanism also explains how bacterial IgG-binding proteins regulate NK cell function and may be broadly applicable to Fcg-receptor-bearing cells.
In Brief
IgG conventionally utilizes its Fab and Fc domains to engage antigens and immune effector cells, respectively. Dai et al. show that the Fc domain alone allows CD16+ NK cells to recognize and lyse virusinfected cells that express IgG-binding proteins.
INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells capable of directly recognizing cancer cells and virally infected cells without prior antigen exposure (Orr and Lanier, 2010) . The functional status of NK cells is regulated by signal inputs from cytokines and a wide variety of NK cell activating or inhibitory receptors, for which many viral or bacterial proteins are natural ligands (Orr and Lanier, 2010) . Almost all circulating NK cells express the low-affinity Fcg receptor (FcgR) IIIA/CD16a (CD16a hereafter), which is required for antibody-dependent cell-mediated cytoxicity (ADCC) (Nimmerjahn and Ravetch, 2008) . CD16a is a type I transmembrane protein whose extracellular domain binds the Fc domain of IgG (IgGFc) at the hinge region (Sondermann et al., 2000) and its transmembrane helix and intracellular domain couple with the signal transducer CD3z (Anderson et al., 1990; Lanier et al., 1989) . In classical ADCC, polyvalent antigen-antibody complexes bind CD16a and consequently cluster CD3z, whose subsequent phosphorylation results in the activation of NK cells and lysis of antibody-coated target cells (O'Shea et al., 1991) . Monomeric binding of CD16a by IgGFc, however, is not able to activate NK cells (Metzger, 1992) . Upon activation, human NK cells undergo dramatic phenotypic and functional changes, including expression of early activation marker CD69 (Testi et al., 1994) and degranulation marker CD107a (Alter et al., 2004) , loss of CD16a and adhesion molecule CD62L (Romee et al., 2013) , secreting cytokine IFN-g, and lysing target cells by releasing pre-stored perforin and granzyme B (Orr and Lanier, 2010) Human NK cells constitute the first line of defense against infection with herpes simplex virus (HSV1). While HSV1 infection in a heathy population is usually self-limited and shows no or very mild symptoms (Gilden et al., 2007) , patients with NK cell deficiencies can suffer severe, recurrent, and sometimes fatal HSV1 infection (Biron et al., 1989) , suggesting a critical role for NK cells in control of HSV1 infection. The HSV1 genome contains 84 open reading frames, encoding 74 unique viral proteins (Szpara et al., 2010) ; only few genes have been studied for their roles in modulating the function of NK cells with some controversial results (Bishop et al., 1983; Chisholm et al., 2007; Fitzgerald-Bocarsly et al., 1991; Huard and Fr€ uh, 2000; Imai et al., 2013; Ló pez-Guerrero et al., 1988) . How NK cells mechanistically recognize and clear primary HSV1 infection (i.e., before antigen-specific immunity is generated) is unclear. Given the increasing importance of HSV1 in the immunotherapy of cancer (Andtbacka et al., 2015) and the lack of approved vaccines for most human pathogens in the herpesviridae family (Gilden et al., 2007) , we set out to systematically dissect the contribution of individual HSV1 genes to NK cell activation.
We developed a cytotoxicity assay, differential cytolysis mediated by ectopic gene expression (DC-MEGE), and screened HSV1 genes for their ability to modulate human NK cell function when individually expressed in human glioma (brain tumor) cells. We found that HSV1 glycoprotein E (gE), which can bind IgGFc, activated human NK cells through direct interaction. We found that IgGFc can bridge gE and CD16a to form the gE-IgGFc-CD16a ternary complex, which conveyed the activation signal for NK cells. In vivo infusion of human IgG1Fc fragments alone protected mice from lethal HSV1 infection in a manner dependent on NK cells and gE, as did other human IgG1 therapeutic antibodies not targeting any HSV1 antigens. Furthermore, we found bacterial IgGFc-binding proteins also activate NK cells through the IgGFc-mediated bridging. Overall, we provide evidence for a basic mechanism by which immune cells expressing FcgR recognize certain primary viral and bacterial infections expressing Fc-binding proteins via bridging mediated by IgGFc in the absence of antigen-specific antibodies or prior sensitization.
RESULTS

HSV1 gE Is a Human NK Cell Activator
We chose glioma as the target cells for HSV1 infection and NK cell activation for three reasons: (1) HSV1 is a neurotropic virus and has been exploited for treating glioma; (2) primary NK cells are relatively inert to native glioma cells; and (3) HSV1-infected glioma causes a rapid migration of NK cells and strong NK activation (Alvarez-Breckenridge et al., 2012) . We developed DC-MEGE to measure how NK cells respond to glioma cells expressing a single HSV1 gene (Figures 1A and S1A-S1D). Each HSV1 gene was cloned upstream of the ''self-cleaving'' T2a sequence and green fluorescence protein (GFP) in the lentiviral expression vector called pCDH. Therefore, GFP reports the expression of viral proteins ( Figure S1A ) (Szymczak et al., 2004) . Following transfection, glioma cells were divided into two equal portions, one cultured alone and the other cultured with primary NK cells ( Figure S1B ). The percentage of GFP + living glioma cells were recorded 5 hr later in parallel as GFP(+NK)% when NK cells are present or GFP(-NK)% when glioma cells are cultured alone. As shown in the sample analysis result ( Figures S1C and S1D ), DC-MEGE is an unbiased assay because of the following: (1) following transfection, GFP + and GFP -cells are treated under the same condition, and (2) cytotoxicity of DC-MEGE is measured by relative change of percent GFP and not affected by initial transfection efficacy. Applying the DC-MEGE assay, we screened 65 HSV1 genes and found that glioma cells expressing UL12, UL30, Us3, Us8, and Us12 were more susceptible to NK cell cytolysis, while expression of UL48, Us5, or Us6 made glioma cells resistant to NK cell cytolysis ( Figure 1B , S1C, and S1D). HSV1 Us8 encodes gE, which alone is a low-affinity humanIgGFc-interacting protein, binding human IgG1, IgG2, and IgG4 at the CH2-CH3 interface (Sprague et al., 2006) . Previous studies proposed that gE can compete with human Fcg receptors (including CD16a) to bind IgGFc, thereby inhibiting NK cell activation via antibody-dependent cellular cytotoxicity (ADCC) (Corrales-Aguilar et al., 2014; Dubin et al., 1991; Frank and Friedman, 1989) . However, our results showed that expression of gE activated NK cells and stimulated lysis of glioma, so we focused on HSV1 Us8 to resolve how gE modulates NK cells mechanistically.
K562 cells are leukemia cells negative for MHC I molecule and widely used as a positive control for NK cell activation (Lozzio and Lozzio, 1979) . A characteristic activating phenotype, including the increase of CD69 and CD107a and the loss of CD62L and CD16a, is shown in human NK cells cultured with K562 or glioma cells expressing Us8 (referred to as glioma Us8 hereafter) ( Figure 1C ). Because the expression of CD69 and CD107a in activated NK cells was highly correlated (Figures S1E and S1F), we chose to combine CD69 and CD107a when summarizing staining results ( Figure 1D ). This activating phenotype was barely shown on NK cells cultured with glioma cell transfected with an empty pCDH vector (glioma pCDH hereafter) (Figures 1C and 1D) . Culture with glioma Us8 also induced NK cells to produce IFN-g ( Figure 1E ). Consistent with the DC-MEGE result, the transfection of Us8 and consequent expression of gE also sensitized both a proneural (84PN) and a mesenchymal 1123 (Mao et al., 2013) human glioma cell line to NK cytotoxicity ( Figure 1F ).
To answer whether gE activated NK cells directly or indirectly, we treated glioma Us8 with isotype or gE-specific mouse monoclonal antibody to block gE and found that NK cytotoxicity toward glioma Us8 was attenuated by gE-specific antibody (Figure 1G ). Furthermore, we purified wild-type (WT) HSV1 F strain virus, of which gE is a major protein component, and coated plates with detergent-inactivated WT virus. NK cells cultured in plates coated with WT virus also showed the activating phenotype. This appeared to be dependent on gE because a mutant HSV1 F strain with targeted deletion of Us8 (Us8 -) (Suenaga et al., 2014) was not able to activate NK cells in the same experimental setting. Further, blocking WT virus with gE-specific antibody also aborted NK cell activation (Figures 1H and S1G) .
Taken together, these results demonstrated HSV1 gE activated human NK cells through direct interaction.
Human IgG Links gE and NK Cell Activation HSV1 gE can heterdimerize with glycoprotein I (gI), and the resultant gE-gI complex binds human IgG with much higher affinity than gE does alone (Johnson et al., 1988; Sprague et al., 2006) . The HSV1 gI is encoded by the Us7 gene, and gI alone does not bind human IgG (Johnson et al., 1988) . Human NK cells cultured with glioma cells expressing Us7 (glioma Us7 hereafter) did not undergo activation ( Figures 1B, S1C , and S1D). Because the IgG-binding property of gE has been linked with an immune evasion role by several studies (Corrales-Aguilar et al., 2014; Dubin et al., 1991; Frank and Friedman, 1989) , our first thoughts were that NK cell activation and IgG binding were two independent functions fulfilled by different structural domains of gE. If this were true, glioma expressing both Us7 and Us8 (glioma Us7+Us8 hereafter), with formation of the high-affinity IgGbinding gE-gI complex, should cause no stronger NK cell activation than glioma Us8 alone, assuming both have equal gE expression. We found, however, that glioma Us7+Us8 activated NK cells much more potently than glioma Us8, although both express a similar amount of gE (Figures 2A, 2B , and S1H), suggesting NK cell activation by gE involves the IgG-binding function of gE. Human IgG was not added to the glioma-NK cell co-culture thus far, however, we found that human IgG molecules were naturally present on the surface of primary human NK cells (Figure 2C) . Washing NK cells briefly with acidic media decreased surface IgG ( Figure 2C ) and increased binding of an anti-human CD16a antibody (3G8) that competes with human IgG for the same binding site on CD16a (Perussia et al., 1984) (Figure 2D ), demonstrating that IgG molecules are anchored on human NK cells via CD16a. Primary NK cells from a variety of healthy human donors had very different amounts of surface IgG ( Figure 2E ), and their response to stimuli varied ( Figure 2F ). We found that the response of human NK cells toward glioma Us8 (measured by the percentage of CD69 + or CD107a + NK cells) directly correlated with the surface density of IgG; the correlation became even stronger when NK cells were cultured with glioma Us7+Us8 ( Figure 2G ). In contrast, the response of NK cells to (H) Summary of phenotypical changes of primary human NK cells after culturing for 7 hr in plates pre-coated with inactivated pure viruses. In some cases, isotype or mouse-Us8-specific antibody was added into plates to block Us8 (n = 5-7). Each dotted line in (D), (E), and (H) links data acquired from the same donor. *p < 0.05, **p < 0.01. Please see also Figure S1 . K562 cells showed no correlation with the surface density of IgG ( Figure 2G ). Taken together, surface IgG on human NK cells links gE and NK cell activation.
CD16a, IgG1Fc, and HSV1 gE Form a Ternary Complex Previous studies assumed that IgG bound by gE could no longer bind human Fcg receptors due to competition or steric hindrance, thus contributing to immune evasion (Corrales-Aguilar et al., 2014; Dubin et al., 1991; Frank and Friedman, 1989) . However, CD16a-binding sites on IgG1Fc are located far away from the CH2-CH3 interface where gE binds IgG1Fc, and structure modeling using the known gE-IgG1Fc (Sprague et al., 2006) and CD16a-IgG1Fc (Sondermann et al., 2000) crystal structures supported that gE and CD16a could bind the same IgG1Fc molecule without interfering with each other ( Figure 3A) .
To validate the existence of such a CD16a-IgG1Fc-gE complex, we tested the binding between gE, IgG1Fc, and CD16a using a flow-cytometry-based method (Figures 3B and 3C) . IgG1Fc(DCD16) is a recombinant human IgG1Fc fragment without the CD16a-binding sites; IgG1Fc has intact CD16a-binding sites; and rituximab is a humanized IgG1 monoclonal antibody against human CD20 that also has intact CD16a-binding sites (Edwards et al., 2004) . All three forms of IgG1Fc could bind glioma Us7+Us8, but none bound glioma Us7, demonstrating that Fc specifically binds gE and that the CD16a-binding sites on IgG1Fc are not involved in binding gE ( Figure 3B ). The CD16a ectodomain did not directly bind either glioma Us7 or glioma Us7+Us8; however, the CD16a ectodomain bound glioma Us7+Us8 only when IgG1Fc or rituximab was present but not when IgG1Fc (DCD16) was present ( Figure 3C ). We also performed similar CD16a-binding tests using glioma cells infected with Us8
-or WT HSV1 and showed gE was required for capturing IgG1Fc and CD16a ( Figure 3D ). Taken together, these results demonstrate the CD16a-IgG1-gE complex exists.
Staphylococcus aureus (S.A) and group G streptococcus also produce human-IgG-binding proteins (protein A and protein G, respectively). Like HSV1 gE, protein A and protein G bind IgGFc mainly at the CH2-CH3 interface (Deis et al., 2015; Sauer-Eriksson et al., 1995) , and structural modeling supported that IgG occupied by CD16a could still bind protein A and protein G (Figures S2A and S2B). In support of the structure modeling, we found that protein A and protein G could bind primary human (E-G) NK cells from healthy human donors were stained for surface IgG immediately after isolation (E) and stained for CD69 and CD107a after co-culturing with specified cells with for 7 hr. (F) Percentages of NK cells positive for CD69 or CD107a after co-culturing with specified cells were plotted against surface IgG intensity of corresponding human donors. Correlation of surface IgG and NK cell activation was calculated using linear regression (G) (n R 20). Each dotted line in (A)-(C) links data acquired from the same donor. *p < 0.05, **p < 0.01. Please see also Figure S1 . NK cells. A prior brief acidic wash of NK cells, which removes surface IgG bound to CD16a ( Figure 2D ), reduced protein A and protein G binding (Figures S2C and S2D) . These results further supported that, contrary to conventional assumptions (Deis et al., 2015) , surface IgG molecules coated on NK cells via CD16a have a freely accessible CH2-CH3 interface to bind gE, protein A, and protein G.
The CD16a-IgG-gE Complex Is Essential for NK Cell Activation by gE To test whether the formation of CD16a-IgG-gE complex is responsible for NK cell activation by gE, we incubated primary human NK cells with an excess of soluble protein A or protein G to occupy all CH2-CH3-binding sites prior to culturing the NK cells with different stimuli. Pre-incubation of NK cells with either soluble protein A or protein G did not change human NK cell activation when co-cultured with K562 cells or cytokines (IL12+IL18) that activate NK cells through STAT4, STAT3, and MAPK pathways (Kalina et al., 2000; Watford et al., 2004) . However, blocking with soluble protein A or G completely inhibited phenotypic changes, cytotoxicity, and IFN-g production of NK cells induced by co-culture with glioma Us8 and glioma Us7+Us8 ( Figures 4A-4D ). Additionally, plates coated with pure and inactivated WT HSV1 could no longer activate NK cells that were pre-incubated with soluble protein A or protein G ( Figures S3D and S3E ).
Experiments described above were all conducted without adding extra human IgG, and NK cell activation by gE was mediated by surface IgG naturally present on primary NK cells (Figure 2C) . During primary HSV1 infection in vivo, infected cells are likely to be coated with human IgG due to the expression of gE and the abundance of IgG in the human body. To test whether the non-immune IgG coating on HSV1-infected glioma, glioma Us8, or glioma Us7+Us8 could provide additional anchoring and activating sites for NK cells, we treated each with IgG1Fc before culture with NK cells. The presence of IgG1Fc fragments indeed further enhanced activation of NK cells by infected or transfected glioma in a gE-dependent manner ( Figures 4E, 4F , S3F, and S3G).
Anti-HSV1 IgG increased NK cytotoxicity to glioma cells infected with HSV1 WT F strain or Us8 -F strain (classical ADCC), but human IgG1Fc and an antibody targeting an irrelevant antigen (i.e., rituximab) increased killing of glioma cells infected with WT F strain but not Us8 -F strain ( Figure 4G ). Similarly, NK cytotoxicity against glioma Us8 and glioma Us7+Us8 cells was also increased when IgG1Fc was present ( Figure 4H ). Although CD3z phosphorylation is a very transient event, we were able to capture specific CD3z phosphorylation induced by glioma Us7+Us8 and positive control H 2 O 2 stimulation (Figures 4I and 4J) . CD3z phosphorylation was not induced by either glioma Us7 or cytokines IL12+IL18, demonstrating the specificity of this staining ( Figures 4I and 4J ). Taken together, CD16a-IgG-gE is a functional complex fully responsible for the NK cell activation by target cells expressing HSV1 gE.
IgG Bridging Promotes the Clearance of HSV1 Infection
In Vivo HSV1 gE does not bind mouse IgG (Chapman et al., 1999) ; however, mouse FcgR binds human IgG with high affinity as reported by others (Ober et al., 2001 ). We also found that injecting mice with human IgG1Fc or whole humanized antibody rituximab did not affect the phenotype of mouse NK cells but did result in the coating of human IgG on mouse NK cells ( Figure S4A ). Therefore, we propose that provision of human IgG or human IgGFc should be able to bridge mouse NK cells and HSV1-infected cells and promote clearance of HSV1 infection both in vitro and in vivo. Consistent with this hypothesis, we found NK cells isolated from C57BL/6 and BALB/c mice displayed enhanced cytotoxicity toward glioma Us7+Us8 when human IgG1Fc was present ( Figure 5A ). Using an HSV1 F strain expressing luciferase (Zerboni et al., 2013) , we demonstrated that administration of rituximab promoted clearance of HSV1 infection in vivo ( Figure 5B ). In a lethal HSV1 infection model, rituximab alleviated the symptoms of infection ( Figures 5C and S4B ) and provided mice complete protection from lethal HSV1 infection ( Figure 5D ). Importantly, this protection is not dependent on Fab of rituximab because human IgG1Fc and daratumumab (a human IgG1 antibody directed against human CD38) demonstrated a similar protection against HSV1 infection ( Figures 5C,  5D , and S4B). HSV1 gE is required for the cell-to-cell spread of HSV1 in vivo (Polcicova et al., 2005) , and Us8 -HSV1 F strain did not cause productive infection in vivo (data not shown); therefore, we could not use the Us8 -F strain in vivo to directly confirm the dependence on gE for this type of protection. However, human IgG3, which does not bind HSV1 gE (Sprague et al., 2006) , failed to provide any protection against HSV1 infection ( Figures 5C, 5D , and S4B). Furthermore, human IgG1Fc was not able to protect mice from lethal infection of mouse cytomegalovirus (MCMV) ( Figure 5E ), another member of the herpesviridae family, which caused a similar progressively fatal infection as seen with HSV1 ( Figure 5D ) but did not produce a protein able to bind human IgG ( Figure S4C ). These results support the notion that the IgG1Fc-mediated protection of HSV1 infection is dependent on the interaction of IgG1Fc and gE. Although human IgG1Fc, daratumumab, and rituximab can all bind HSV1 through gE, this binding had no direct effect on the infectivity of HSV1 in vitro ( Figure 5F ), indicating that the protective role of these reagents against HSV1 infection in vivo must be executed by immune cells. When NK cells were depleted by antiasialo GM1 antibody (Kasai et al., 1981) during the infection (Figure S4D) , human IgG1Fc failed to protect mice from lethal HSV1 infection ( Figure 5G ). These results demonstrate that human IgG1Fc functions as a bridge, engaging viral-infected cells and NK cells, which provide robust protection against primary HSV1 infection before the adaptive immune system generates a pathogen-specific antibody. We focused only on NK cells in this study; however, human monocytes and macrophages express high-affinity FcgRI/CD64, which binds IgG in the same fashion as CD16a (Kiyoshi et al., 2015) . We therefore do not exclude the possibility of their involvement in clearance of HSV1 infection through IgGFc-mediated bridging.
Taken together, we have described a previously unappreciated mechanism by which NK cells recognize HSV1-infected cells utilizing IgGFc to form a bridge between CD16a and the Fc-binding protein gE, resulting in NK cell activation and viral clearance ( Figures S4E-S4H ). It differs from the classical IgG function of ADCC in that it does not require any antigen-specific antibody and limits virus infection before the establishment of adaptive immunity. We propose to call this type of NK cell recognition, activation, and cytotoxicity Fc bridged cell-mediated cytotoxicity (FcBCC).
Bacterial IgG-Binding Proteins Activate NK Cells through Crosslinking Surface IgG
In the 1970s and 1980s, protein A was extensively studied for its ability to induce ''natural killing activity'' of peripheral blood mononuclear cells (PBMCs). The consensus from these earlier studies was that the natural killing activity of PBMCs could only be increased when PBMCs were exposed to soluble protein A for at least 20 hr Kasahara et al., 1981 Kasahara et al., , 1982 Kay et al., 1977; Olinescu et al., 1983; Patel et al., 1981; Ratliff et al., 1981) . However, whether the enhanced ''natural killing activity'' is contributed by NK cells or whether protein A activates NK cells directly or indirectly through other mononuclear cells remained unknown.
Given our demonstration that soluble protein A and protein G bind to IgG molecules presented on the surface of NK cells (Figures S2C and S2D) , we asked if this IgG bridge might also be responsible for the activation of NK cells by bacterial IgG-binding proteins. However, we did not observe activation of purified human NK cells by soluble protein A or protein G even after 20 hr of culture ( Figures 6A-6C ). NK cell activation through CD16a minimally requires two CD16a-binding sites physically close enough so as to cluster CD3z and initiate phosphorylation (Metzger, 1992) . HSV1 gE expressed on cells or coated in plates are de facto multimers, able to cluster many CD16a molecules and initiate activation (Figures 2A and 2B) . We therefore assessed the ability of multimeric forms of protein A or protein G, as would exist in bacteria or as adhered to a plate, to activate NK cells.
Purified primary human NK cells were indeed activated after culturing in plates pre-coated with protein A or G ( Figures 6A  and 6B ), producing IFN-g ( Figure 6C ) and showing enhanced NK cytotoxicity ( Figure 6D ). These NK cell functional enhancements were abrogated when protein A-or G-coated plates were blocked with mouse serum (Figures 6A-6C Figure S5C ). We tested the binding of CD16a to S.A bacteria in the presence of human IgG (rituximab), IgG1Fc, or IgG1Fc (DCD16) and confirmed that a CD16a-IgGFc-protein A complex formed ( Figure 6E ). We found that WT S.A induced activation of NK cells, which was dependent on protein A because NK cell activation was not induced by Spa -strain or by WT S.A blocked with mouse serum (Figures 6F and 6G ). NK cell activation by WT S.A was also blocked by pretreatment with soluble protein A or protein G ( Figure S5D ). CD3z phosphorylation of primary human NK cells cultured under these conditions completely mirrored the phenotypic results (Figure 6H ). Taken together, WT S.A, polymerized protein A, and protein G use the same IgG bridging mechanism as HSV1 to activate NK cells. Although protein A has been shown to bind tumor necrosis factor a receptor 1 (TNFR1) and induce inflammatory signals via the NF-kB pathway (Gó mez et al., 2004), TNFR1 should not be involved in NK cell activation by protein A, for the following reasons: (1) human NK cells barely express TNFR1, as previously described (Liu and Tang, 2014) and validated here ( Figure S5E ), (2) soluble protein A does not activate NK cells, (3) protein G does not bind TNFR1 (Gó mez et al., 2004) , and (4) we showed here polymerized protein G and polymerized protein A used the same mechanism to activate NK cells. However, TNFR1 was expressed on monocytes and granulocytes ( Figure S5E ), which therefore can be activated by soluble protein A and in turn activate bystander NK cells, potentially explaining why prolonged (20 hr) protein A treatment was required to increase ''natural killing activity'' of PBMCs Kasahara et al., 1981 Kasahara et al., , 1982 Kay et al., 1977; Olinescu et al., 1983; Patel et al., 1981; Ratliff et al., 1981 Litwin et al., 1992; Loukas et al., 2001; Olson et al., 1997; Sprague et al., 2008) . Given the presence of IgGbinding proteins in many different pathogens, FcBCC may have broad implications in controlling infectious diseases. In addition, protein A and protein G are widely used in the industry for antibody purification; our findings may provide insights for other uses for these two proteins.
HSV1 gE complexes have been shown to participate in ''antibody bipolar bridging,'' whereby a single anti-HSV1-specific IgG antibody simultaneously binds to an HSV1 antigen using its Fab domain and to gE via its Fc domain (Frank and Friedman, 1989) . It has been proposed that such antibody bipolar bridging could block access of the Fc portion of the anti-HSV1-specific IgG antibody to FcgR expressed on innate immune effector cells and thereby reduce classical ADCC and presumably provide a mechanism for immune evasion following HSV1 infection (CorralesAguilar et al., 2014; Dubin et al., 1991) . However, previous studies suggesting an inhibition of NK cell activation by HSV1 gE have been conducted in the presence of anti-HSV1-specific antibody (Corrales-Aguilar et al., 2014; Dubin et al., 1991; Frank and Friedman, 1989) . These studies all relate to classical ADCC, one of the strongest NK cell activation signals. Considering that the configuration of gE-IgGFc may not be as optimal as that of the antigen-antibody complex to be recognized by CD16a, it is not surprising that an immunosuppressive role has been assigned to gE under such conditions. The function of HSV1 gE binding non-immune IgG under the condition of primary viral infection, however, was not pursued in these studies.
Our knowledge regarding functions of gE other than IgG binding is limited, although few studies showed that gE was required for the spread of HSV1 between cells in vivo (Collins and Johnson, 2003) . Why does HSV1 encode gE to limit the infection of human host by itself? Viruses are completely dependent on host cells for replication and transmission. Weakening the host can also weaken the virus, and in the extreme, extinction of host leads to the extinction of the virus. From the standpoint of evolution, viruses can not only cause disease and harm the host, but they must also benefit the host in some way. A recent study lends support to a less popular notion, suggesting that viral infection can compensate the host with a stronger immune response (Furman et al., 2015) . In the current study, we found gE limited the uncontrolled replication and spread of HSV1 during its lytic stage of infection. Under this circumstance, the human host is not overwhelmed and HSV1 infection can proceed to its latent stage of infection. Consequently, gE may play a beneficial role during HSV1 infection in that it allows the virus to maintain a constant existence in the human population.
Our study also establishes a functional role for surface IgG on the NK cell and other immune cells. Each monomeric IgG has only one FcgR-binding site and thus prevents surface-coated IgG from binding another FcgR, thereby causing autoimmune disease (Sondermann et al., 2000) . CD16a binds IgG with low affinity, so there is an equilibrium between binding and disassociation, and only a certain percentage of CD16a on NK cells are occupied by IgG. As such, other CD16a molecules are unoccupied by IgG and thus can be stained by the 3G8 mAb. The same phenomenon happens to host cells expressing gE following HSV1 infection. Therefore, FcBCC can be triggered bidirectionally: gE binds the IgG-CD16a complex, and unoccupied CD16a binds the IgG-gE complex.
It is noteworthy that gE, protein A, and protein G share no sequence or structure similarity, yet each of these IgG-binding proteins can be recognized by the Fc domain of IgG that is bound to the surface of NK cells. Human cells may also express such IgG-binding proteins. Due to the importance of Fc binding in mediating every facet of immune responses (Nimmerjahn and Ravetch, 2008) , screening human proteins that are able to form a ternary complex with IgGFc and human FcgRs or complement may identify auto-antigens, define autoimmune diseases, and uncover the cause of infusion reactions to therapeutic monoclonal antibodies, leading to the development of therapeutic interventions and improved antibody-based therapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: beginning of coculture. Cell supernatants were collected after 20 hr' culture, and quantification of human IFN-g was performed using ELISA Kit.
DCMEGE assay 24h after transfection, glioma cells were resuspended and centrifuged down at 50 g for 5 min to remove cell debris and dead cells. Subsequently, 1*10 4 glioma cells were resuspended with 100 mL DMEM/F12 media and seeded into each well of a U bottom 96-well plate. Purified human NK cells were resuspended in complete RPMI1640 media to the final concentration of 5*10 6 /ml, and 100 mL of NK cells were added to culture with transfected glioma cells. In a parallel control experiment, 100 mL complete RPMI1640 media, instead of human NK cells, were added to the seeded glioma cells. Culture samples were collected using LSRII at 5th hour of culture. Living glioma cells were gated in based on their FSC and SSC and measured for the percentage of GFP+ cells ( Figure S1B ). Differential cytotoxicity contributed by the expression of individual viral gene is calculated with the formula: DGFP = ððGFP%ð + nkÞ À GFP%ðÀnkÞÞ=ðGFP%ðÀnkÞÞÞ Ã 100%.
HSV1 virus production, purification and inactivation Vero cells were seeded at a density of 7*10 6 cells per 100 mm dish and inoculated with 2.5 pfu per cell of HSV-1 F strain or Us8-mutants (Suenaga et al., 2014) . At 24 hr post-inoculation, culture media and cell debris were collected. After three freeze-thaw cycle to release viruses, cell debris were removed by low speed centrifugation (2,000 3 g for 5 min), supernatants were loaded on a 5 mL 35% sucrose gradient and centrifuged in a Beckman SW27 rotor at 25,000 rpm for 1 hr. Virus pallet was collected, washed and concentrated in PBS. Pure viruses were inactivated with 0.2% trition-100 for 30min at room temperature, and subsequently diluted to 0.1ug protein /ml PBS for coating plates.
Plaque assay for HSV1 Sequentially diluted viruses were loaded on single layer of vero cells and incubated at 37 c; pooled human IgG (final concentration 0.1%) was added 1h later to restrain viruses spread. Plaques were counted after 48 hr culture. To determine the effect of human IgG3, human IgGFc, Rituximab, daratumumab, and human IgG (GamaStan) on the infectivity of HSV1, these reagents were added into sequentially diluted viruses at 1ug/ml and incubated at room temperature for 30min prior to plaque assay. Treated viruses were tittered with standard plaque assay and all results were normalized to PBS as the control.
Chromium release cytotoxicity assay Target glioma cells were either transfected with HSV1 genes at 24 hr, or infected with HSV1 at MOI = 1 at 12 hr before radiolabelling. Target cells were labeled by incubating 5*10 5 cells in 50 mCi 51 Cr for 90min at 37 C. Radiolabeled cells were washed 3 times and resuspended in complete RPMI 1640 media, and seeded in U bottom 96-well plates at a concentration of 5*10 3 cells/100ul media/well. In some cases, antibodies or IgG products (5ug/ml) were added into radiolabeled target cells and incubated on ice for 30 min for binding or blocking certain interactions. Human or mouse NK cells were added in at specified effector-to-target ratios (E:T, x axis on figures) and incubated at 37 C for 4-6 hr. Each E:T ratio were run in triplicates and data represent two independent experiments. After incubation, plates were centrifuged to pellet the cells to the bottom of the plate, and supernatants were collected from each of the wells and quantitated using a gamma counter. Radiolabelled cells were treated with 1% SDS as a measure of maximal cytolysis, or incubated without NK cells were used to measure spontaneous release. Cytolysis was calculated with the formula: cell lysis = ððtarget release À spontaneous releaseÞ=ðMaximal release À spontaneous releaseÞÞ Ã 100%. Cytolysis data were presented as mean of triplicates at each E:T ratio and each experiment was repeated with NK cells from at least two different donors and only one representative was shown.
Structure Modeling
All docking predictions were conducted on the ZDOCK server (Pierce et al., 2014) , and crystal structure of CD16a-Fc (PDB ID: 1E4K) was used as the host. For modeling gE-Fc-CD16a complex, gE subunit of gE-Fc (PDB ID: 2GJ7) was uploaded to the ZDOCK server to dock 1E4K. HSV1 gE residues 225, [245] [246] [247] [249] [250] 256, 258, 311, 316, [318] [319] [320] [321] [322] 324, [338] [339] [340] [341] [342] 307, [309] [310] [311] [314] [315] 382, 428 , and 433-436 were specified as contact residues (Sprague et al., 2006) . For modeling protein A-Fc-CD16a complex, protein A domain C of protein A-Fc complex (PDB ID: 4WWI) was used to dock 1E4K. Protein A domain C residues Q9, Q10, N11, F13, Y14, and L17, and IgGFc residues S254, Q311, L432, and N434, were defined as contacting residues (Deis et al., 2015) . For modeling protein G-Fc-CD16a complex, protein G C2 fragment of crystal structure of protein G-Fc complex (PDB ID: 1FCC) was used to dock 1E4K. Protein G C2 residues 27, 28, 31, 32, 35, 40, 42, 43 and IgGFc residues 253, 254, 380, 382, [433] [434] [435] [436] , were defined as contacting residues (Sauer-Eriksson et al., 1995) . The top-scoring complexes were manually examined for consistency with original crystal structures. All structure images were generated using PyMol.
Interaction of human CD16a, IgG and IgG-binding proteins from pathogens Transfected glioma cells, infected glioma cells, or bacteria were first incubated for 30min on ice with PBS with or without IgG1Fc (DCD16), IgG1Fc, rituximab, respectively. After one wash with FACS buffer, samples were incubated with Alex647 labeled mouse anti-human IgGFc (209-605-098, Jackson ImmunoResearch) in the presence of excess unlabeled mouse serum to detect the binding between Fc with gE or protein A. Otherwise, cells or bacteria were further incubated with biotinylated CD16a and apc-streptavidin (554067, BD) on ice for 20min to detect binding of CD16a to IgG. Stained cells or bacteria and relevant staining controls were checked on LSRII (BD).
CD3z phosphorylation staining
Half million NK cells were rested at 37 C for 1h and stimulated with H 2 O 2 (11mM), IL12 (10ng/ml)+IL18 (10ng/ml), 2*10 5 transfected glioma cells, or 1*10 8 cfu of bacteria for 1h. NK cells were fixed with Phosflow Fix Buffer I, permeabilized with Phosflow Perm Buffer III, blocked with normal mouse immunoglobulin, and then stained with anti-CD 3z (pY142) and anti-CD3z. Phosphatase inhibitor (Roche) was supplemented in all the staining steps.
Mouse experiments
For bioluminescence imaging to track virus load, BALB/c mice were i.p injected with 1.2*10 5 pfu of R8411 viruses (Zerboni et al., 2013) . BALB/c mice were i.p injected with 200ug rituximab at 4 hr prior to virus challenge, and at 24 hr after virus challenge. Each mouse was given 3mg luciferin potassium 10 min prior to isoflurane anesthesia to ensure consistent photon flux. Images were taken at OSU Small Animal Imaging Facility using an IVIS Spectrum (Perkin Elmer) at 84h post infection. Each group was recorded for 4 sections of 2 min exposure. Bioluminescence values were measured from the whole mouse and calculated as photon flux (photons/s/) using Living Image 4.0 (Perkin Elmer).
For survival study, BALB/c mice were i.p injected with 3*10 6 pfu HSV1 F strain viruses or 5*10 5 pfu MCMV. PBS, 200ug human IgG3, 200ug human IgGFc, 200ug rituximab or 200ug daratumumab were given via i.p injection at 4 hr prior to virus challenge, and at 24 hr and 72 hr after virus challenge. Mice were weighed every 24h beginning on the day of infection, and monitored for neurological symptoms (scoring from 0 to 5: 0 = no symptoms; 1 = ruffled fur, hunched posture, but can easily be made to move around; 2 = hunched and slow to move; 3 = hunched, some movement, and labored breathing; 4 = hunched, labored breathing, and little or no movement; 5 = moribund or dead, as described in [Karaba et al., 2012] ).
To study the involvement of NK cells in mediating the protection of HSV1 infection by human IgGFc, mice were given i.p injection of 20ul anti-Asialo GM1 antibody or equal volume of PBS at 24 hr before virus challenge. For the in vitro mouse NK cell stimulation and cytotoxicity, NK cells were enriched from spleens of 8 to 12 weeks old C57BL/6 and BALB/c mice using NK cell isolation kit (Miltenyi Biotec) following manufacturer's instruction. Purified mouse NK cells were cultured the same as human NK cells described above to 51 Cr release cytotoxicity assay.
QUANTIFICATION AND STATISTICAL ANALYSIS
Two-sample t test was used to compare two independent groups and paired t test was used to compare two paired groups. Data transformation was performed if the original distribution is non-normal. Linear mixed models were used to account for the covariance structure due to repeated-measures from the same donor when three or more groups were compared. Kaplan-Meier method was used to estimate survival functions and log-rank test was used to compare survival curves of different groups. P values were adjusted for multiple comparisons by Holm's procedure. A p value of < 0.05 was considered significant. Experiments were repeated at least three or more times. Data are displayed as mean ± SEM.
